This commentary discusses of the impact of COVID-19 on type 1 diabetes (T1D) care in low-middle income countries (LMICs), due to the exacerbations of COVID on access to insulin, blood glucose monitoring, and availability of expert clinical care. Through various country examples, the authors describes these challenges and their evolving responses.